Elghetany M T
Department of Pathology, University of Texas Medical Branch, Galveston 77555-0743, USA.
Leuk Res. 2000 Nov;24(11):975-7. doi: 10.1016/s0145-2126(00)00062-x.
There is a growing interest in studying cell cycle and apoptosis in the myelodysplastic syndromes (MDS). p53 has been a major target of several studies. We examined the impact of antibody selection on p53 overexpression in bone marrow (BM) biopsies of 28 patients with refractory anemia (RA) in addition to 10 cases of aplastic anemia (AA) using three antibodies DO-7, PAb 1801, and PAb 240. DO-7 was positive in 68%, PAb 1801 in 18% and PAb240 in 4% of RA patients. All three antibodies were negative in AA. We conclude that antibody selection is an important variable in studying p53 in MDS regardless of the method of fixation or decalcification of BM trephine biopsies.
对骨髓增生异常综合征(MDS)中细胞周期和细胞凋亡的研究兴趣日益浓厚。p53一直是多项研究的主要靶点。我们使用三种抗体DO-7、PAb 1801和PAb 240,研究了抗体选择对28例难治性贫血(RA)患者以及10例再生障碍性贫血(AA)患者骨髓(BM)活检中p53过表达的影响。DO-7在68%的RA患者中呈阳性,PAb 1801在18%的患者中呈阳性,PAb240在4%的患者中呈阳性。所有三种抗体在AA患者中均为阴性。我们得出结论,无论骨髓环钻活检的固定或脱钙方法如何,抗体选择都是研究MDS中p53的一个重要变量。